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Abstract
Background: Clostridium difficile (C. difficile) infection (CDI) is the leading cause of nosocomial diarrhea in the
United States. This study aimed to examine the incidence of CDI and evaluate mortality and economic burden of
CDI in an elderly population who reside in nursing homes (NHs).
Methods: This was a population-based retrospective cohort study focusing on US NHs by linking Medicare 5%
sample, Medicaid, Minimum Data Set (MDS) (2008–10). NH residents aged ≥65 years with continuous enrollment in
Medicare and/or Medicaid Fee-for-Service plan for ≥12 months and ≥2 quarterly MDS assessments were eligible for
the study. The incidence rate was calculated as the number of CDI episodes by 100,000 person-years. A 1:4
propensity score matched sample of cohorts with and without CDI was generated to assess mortality and health
care costs following the first CDI.
Results: Among 32,807 NH residents, 941 residents had ≥1 episode of CDI in 2009, with an incidence of 3359.9 per
100,000 person-years. About 30% CDI episodes occurred in the hospital setting. NH residents with CDI (vs without
CDI) were more likely to have congestive heart failure, renal disease, cerebrovascular disease, hospitalizations, and
outpatient antibiotic use. During the follow-up period, the 30-day (14.7% vs 4.3%, P < 0.001), 60-day (22.7% vs 7.5%,
P < 0.001), 6-month (36.3% vs 18.3%, P < 0.001), and 1-year mortality rates (48.2% vs 31.1%, P < 0.001) were
significantly higher among the CDI residents vs non-CDI residents. Total health care costs within 2 months
following the first CDI episode were also significantly higher for CDI residents ($28,621 vs $13,644, P < 0.001).
Conclusions: CDI presents a serious public health issue in NHs. Mortality, health care utilization, and associated
costs were significant following incident CDI episodes.
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Background
Clostridium difficile (C. difficile) infection (CDI) is the
leading cause of nosocomial diarrhea in the United
States and has surpassed the infection rate of other
health care-associated infections (HAI) such as
methicillin-resistant Staphylococcus aureus [1, 2]. In a
recent national prevalence survey, C. difficile was the
most commonly-reported pathogen, accounting for 12%
of HAIs and an estimated 80,400 hospital-onset infec-
tions [3]. C. difficile was responsible for almost a half-
million infections and approximately 28,000 deaths in
2011 [4]. The emergence of the epidemic BI/NAP1/027
strain has been associated with the increased incidence,
severity, and mortality of CDI [5]. The increasing inci-
dence of CDI also imposes a large financial burden on
the health care system [6]. In 2008, the excess health
care costs for CDI in acute care facilities alone were
approximately $4.8 billion [7].
The elderly represent the population at greatest risk
for CDI, accounting for the highest disease morbidity
and mortality. Moreover, residents of nursing homes and
other long-term care (LTC) facilities are more prone to
CDI due to advanced age, frequent hospitalization,
prevalent comorbid illnesses, extended stays, and fre-
quent exposure to antibiotics [1]. In 2013, Garg et al.
* Correspondence: holly.yu@pfizer.com
1Pfizer Inc, Arcola Road, Collegeville, PA 19426, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yu et al. BMC Geriatrics  (2016) 16:193 
DOI 10.1186/s12877-016-0367-2
determined that there was a predominantly higher num-
ber of patients diagnosed with LTC-acquired CDI
(46.1%) compared to community-acquired (33.3%) or
hospital-acquired (20.6%) CDI [8]. Additionally, state-
wide surveillance in Ohio has found that there were
more cases of CDI diagnosed in LTC facilities than in
acute-care settings [9]. The increasing trends of CDI-
incidence in LTC facilities such as nursing homes high-
light the need for optimal C. difficile infection control
measures [8].
Previous studies have focused on the costs related to
CDI in acute-care facilities [10, 11]. However, to our
knowledge, there are no recent studies assessing the
costs of CDI in nursing homes. Therefore, the objectives
of this study were to examine the incidence of CDI and
evaluate the mortality and economic burden of CDI in
an elderly population residing in nursing homes.
Methods
Study design and data sources
This population-based retrospective cohort study in-
cluded adults aged ≥65 years enrolled in Medicare or
with dual eligibility with the Medicaid fee-for-service
(FFS) health plan during 2008–2010. A Medicare 5%
random sample was used, and all eligible enrollees were
required to have both Part A (hospital insurance) and
Part B (supplementary medical insurance) during the
study period [12]. Because some Medicare enrollees,
may also be covered by Medicaid due to socioeconomic
factors, we linked the Medicare 5% sample with the
100% Medicaid claims data.
To identify Medicare enrollees residing in nursing
homes, we linked the 5% Medicare sample and 100%
Medicaid with the 100% Minimum Data Set (MDS) and
required ≥2 consecutive MDS quarterly assessments in
the 12 months prior to the CDI diagnosis. The MDS is a
federally-mandated nursing home clinical assessment
performed on all residents at admission, discharge,
annually, and quarterly, regardless of the payer.
Identification of CDI episodes
The primary outcome was the incidence of CDI, identi-
fied as residents with ≥1 medical claim for CDI
(International Classification of Diseases, 9th Revision,
Clinical Modification [ICD-9-CM] code: 008.45) in
Medicare or Medicaid data, or identified CDI (1 = yes) in
MDS data from January 1, 2009 through December 31,
2009. An incident CDI episode was defined as a patient
with no occurrences of CDI within 60 days prior to the
first CDI claim. Among patients with multiple episodes
of CDI, each episode was considered as incident if there
was at least a 60-day gap between the 2 episodes. We
also identified the setting (eg, inpatient, nursing home)
of infection onset using the first CDI claim setting.
Case-control analysis
As a secondary objective, we examined mortality at 30,
60, and 180 days, and at 1 year following the onset of
the index CDI episode. Since mortality information is
derived from the Medicare enrollment file which is up-
dated by the Social Security Administration, we were
able to capture all deaths. We also analyzed all-cause
health care costs and utilization stratified by health plan
(eg, Medicare and Medicaid) within 2 months following
the first incident episode among those with CDI (cases)
and those without CDI (controls). For this analysis, in
contrast to the incidence computation, residents were
required to have no diagnosis of CDI within the
12 months prior to the first incident episode (index date)
in 2009. The 12 months prior to this index date was
used as an observation period to allow sufficient time to
determine baseline demographic and clinical characteris-
tics and health care utilization parameters. Residents
with CDI episodes identified in the MDS typically lacked
complete Medicare and Medicaid data; therefore, these
residents were excluded from this portion of the ana-
lysis. Eligible residents enrolled in Medicare or Medicaid
without a CDI diagnosis between January 1, 2008 and
December 31, 2010, served as the control group and
were randomly assigned an index date in 2009.
Statistical analyses
The incidence rates of CDI were calculated as the num-
ber of residents with a CDI episode per 100,000 person-
years and stratified by age, gender, race, and region. For
the case-control analysis, each CDI case resident was
matched to 4 non-CDI control residents using a ‘greedy’
match method [13]; CDI cases were matched to non-
CDI controls within 0.001 units of the propensity score
[14]. The propensity score was calculated via a logistic
regression model of factors associated with the risk of
CDI, including the residents’ age, gender, race, US
census region, comorbidities using the Charlson Comor-
bidity Index (CCI) score, prior hospitalizations, nursing
home stays, antibiotic exposure, gastric acid suppressant
use within 90 days and 1 year prior to the incident CDI,
individual comorbidities, and comorbid conditions
included the MDS data.
Chi-square tests were used to evaluate differences in
categorical variables. Student t-tests were used for evalu-
ating differences in continuous variables. In addition to
p-values, standardized differences were calculated for
each variable. A standardized difference of >10% was
used to assess significant practical differences in the
case-control comparison [15].
Statistical significance was set a priori at the alpha
<0.05. All analyses were performed using Statistical
Analysis System (SAS) version 9.3 (SAS Institute Inc.,
Cary, NC).
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Results
CDI incidence rates
We identified 1,051 incident episodes of CDI among 941
residents with ≥1 CDI episode in a cohort of 32,807 resi-
dents who met the eligibility criteria. The annual
incidence density of CDI was 3,752.7 episodes per
100,000 person-years and 3,359.9 residents per 100,000
person-years (Table 1). Across the age strata, an inverse
linear trend was observed: the incidence ranged from a
low of 3,414.9 episodes per 100,000 person-years among
residents aged ≥85 years to a high of 4,247.5 episodes/
per 100,000 person-years among those aged 65–74 years.
Incidence was slightly higher among men than women
and lower among whites as compared to blacks or other
race categories. Geographically, the incidence density of
CDI was highest in the Northeast (4,641.1 per 100,000
person-years), and lowest in the Midwest (3,306.8
episodes per 100,000 person-years). The majority of CDI
episodes occurred in a nursing home (71.7%), and 28.3%
occurred in an inpatient hospital setting.
Case-control analysis
After accounting for the inclusion and exclusion criteria,
a sample of 789 residents with an incident CDI episode
and 30,258 without were included for this analysis. The
mean age of the residents with and without CDI was
83.1 years and 83.6 years, respectively. Geographically, a
higher proportion of CDI residents resided in the
Northeast region (36.1% vs 28.5%, P < 0.001), whereas a
higher proportion of non-CDI residents resided in the
Midwest (34.3% vs 27.8%, p < 0.001; Table 2). Approxi-
mately two-thirds of residents had Medicaid coverage
along with their Medicare insurance.
Residents with CDI were more often diagnosed with
comorbidities than those without CDI (CCI scores: 4.6 ±
2.8 in CDI vs 3.2 ± 2.4 in non-CDI groups, P < 0.001;
Additional file 1: Table S1). The hospitalization burden
among those with CDI within the preceding 1 year
(64.8% vs 32.4%, P < 0.001) or 90 days (43.2% vs 10.9%,
P < 0.001) was significantly higher compared to residents
without CDI. After propensity score matching (PSM),
653 residents with an incident CDI episode and 2,612
residents without a CDI episode were compared for the
secondary objectives.
Mortality
During the 12-month follow-up period, the 30-day
(14.7% vs 4.3%, P < 0.001) mortality rate was significantly
higher among the propensity score (PS)-matched CDI
residents as compared to the PS-matched non-CDI resi-
dents, so are mortality rates at 60-day, 6-month and 1-
year follow up (Fig. 1).
Health care utilization
Among Medicare-covered claims, during the 2-month
follow-up period, the number of inpatient claims was
significantly higher among PS-matched CDI residents
compared to PS-matched non-CDI residents (0.66 vs
0.13, P < 0.001). Similarly, the number of skilled nursing
facility (SNF) and carrier claims was significantly higher
among PS-matched CDI residents. Among the Medicaid
covered claims, the number of inpatient claims was sig-
nificantly higher among PS-matched CDI residents as
compared to PS-matched non-CDI residents (0.23 vs
0.08, P < 0.001); however, the number of pharmacy
claims was significantly higher in the PS-matched non-
CDI cohort as compared to the PS-matched CDI cohort
(2.37 vs 1.74, p < 0.001; Table 3).
Health care costs
For Medicare covered expenses, inpatient costs ($9,678
vs $1,435, P < 0.001), SNF claims ($4,939 vs $1,452, P <
0.001), carrier claims ($2,463 vs $835, P < 0.001), and
total costs ($18,993 vs $5,716, P < 0.001) during the 2-
month follow-up period were significantly higher among
CDI residents compared to non-CDI residents. For
Medicaid-covered expenses, inpatient stay costs ($2,715
vs $316, P < 0.001) were significantly higher among those
with CDI during the 2-month follow-up period (Table 3).
After summing all these costs from Medicare and
Medicaid, inpatient stays represented the highest incre-
mental cost increase ($10,642) followed by SNF costs.
Table 1 Incidence Rate of CDI Stratified by Age, Sex, Race, and
Region
Incident CDI Cases per
100,000 Person-years
of Observation




Incidence by Age Group
65–74 4247.5 3792.4
75–84 4048.1 3598.3













CDI Clostridium difficile infection
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The total CDI-attributable costs equaled $14,977, and
most of these incremental costs were paid by Medicare.
Discussion
This study estimated the burden of CDI among nursing
home residents. To our knowledge, this is the first study
to estimate the health care costs and utilization associ-
ated with each CDI episode in this elderly population.
We reported an incidence rate of 3,753 cases per
100,000 person-years (1.03 cases per 10,000 resident
days), and 3,360 CDI patients per 100,000 person-years
among nursing home residents. A study conducted by
Kim et al. reported that the yearly incidence rate of
LTC-associated CDI increased from 0.4 cases per 10,000
person-years in 2008 to 0.8 cases per 10,000 person-
years in 2009 [1]. According to the results from another
study conducted in 2010, the incidence rate of CDI in
nursing homes was 2.3 cases per 10,000 resident days
[16]. These results suggest a persistent increasing trend
of CDI incidence among the nursing home residents in
recent years. The emergence of new, severe, and hyper-
virulent epidemic strains of C. difficile over the past
years has particularly affected older adults and played a
role in the increasing CDI rates [17].
Previous literature has noted the increased incidence
of CDI; however, the majority of these studies focused
on acute care settings [7, 10, 18]. Besides hospitalized
patients, a trend of increased CDI incidence has been
observed in nursing homes and communities [8, 19].
CDI outbreaks have been reported in nursing facilities
since 1986 [5]. An influx of CDI in nursing homes from
Table 2 Baseline Demographic Characteristics Between CDI and Non-CDI Residents Before and After PSM
Unmatched Groups 1:4 PSM-Matched Groups
Non-CDI Residents CDI Residents Non-CDI Residents CDI Residents
(N = 30258) (N = 789) (N = 2612) (N = 653)
N/Mean % N/Mean % P-value Std. Diff. N/Mean % N/Mean % P-value Std. Diff.
Age (mean ± SD) 83.6 ± 9.3 83.1 ±
8.8
0.1103 5.6 83.5 ± 9.1 83.6 ±
8.7
0.9206 0.4
65–74 5979 19.8% 156 19.8% 0.9934 0.0 501 19.2% 116 17.8% 0.4082 3.6
75–84 8541 28.2% 237 30.0% 0.2648 4.0 770 29.5% 200 30.6% 0.5657 2.5
85 or older 15738 52.0% 396 50.2% 0.3117 3.6 1341 51.3% 337 51.6% 0.9025 0.5
Gender
Female 23020 76.1% 585 74.1% 0.2089 4.5 1946 74.5% 498 76.3% 0.3535 4.1
Region
Northeast 8610 28.5% 285 36.1% <0.001 16.4 895 34.3% 230 35.2% 0.6453 2.0
Midwest 10375 34.3% 219 27.8% 0.0001 14.2 739 28.3% 185 28.3% 0.9845 0.1
South 10239 33.8% 261 33.1% 0.6563 1.6 905 34.6% 224 34.3% 0.8685 0.7
West 1033 3.4% 23 2.9% 0.4453 2.8 73 2.8% 14 2.1% 0.3557 4.2
Race/Ethnicity
White 24337 80.4% 612 77.6% 0.0455 7.0 2065 79.1% 527 80.7% 0.3523 4.1
Black 4198 13.9% 128 16.2%% 0.06 6.6 392 15.0% 92 14.1%% 0.5545 2.6
Other 1723 5.7% 49 6.2% 0.5373 2.2 155 5.9% 34 5.2% 0.4765 3.2
Insurance Type
Medicare only 5812 19.2% 151 19.1% 0.9607 0.2 460 17.6% 129 19.8% 0.2025 5.5
Medicaid only 5221 17.3% 112 14.2% 0.0245 8.4 366 14.0% 84 12.9% 0.4463 3.4
Medicare and Medicaid dual
19225 63.5% 526 66.7% 0.0712 6.6 1786 68.4% 440 67.4% 0.6252 2.1
CDI Clostridium difficile infection, SD standard deviation; Std. Diff standardized difference, PSM propensity score matching
Fig. 1 Adjusted 12-month Follow-up Mortality After the Index date
Between Non-CDI and CDI Residents. CDI: C. difficile infection
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acute care may lead to subsequent transmission within
the facility, leading to an overall increase in nursing
home CDI rates. Residents may also acquire CDI during
their stay at the nursing home, adding to the increased
incidence rate [1]. Several factors may have contributed
to the shift from primarily a hospital-acquired infection
to a nursing home-acquired infection, such as an
increase in the elderly population admitted to nursing
home facilities, an increase in use of multiple medica-
tions (especially antibiotics and proton pump inhibitors
[PPIs]), and multiple comorbidities among the elderly
population [8]. Because nursing home residents are one
Table 3 Adjusted Utilization and Costs After the Initial CDI Diagnosis Between Non-CDI and CDI Residents
Non-CDI Residents CDI Residents
(N = 2,612) (N = 653)
N/Mean %/SD N/Mean %/SD P-value Std diff
2- months Follow-up All-cause Health Care Utilization
Medicare: Number of Claims
# inpatient claims 0.13 0.41 0.66 0.88 <0.001 77.03
# outpatient claims 1.39 2.27 1.57 2.62 0.1039 7.42
# SNF claims 0.33 0.80 0.85 1.31 <0.001 47.96
# HSP claims 0.15 0.57 0.20 0.58 0.06 8.29
# HHA claims 0.01 0.10 0.00 0.06 0.181 4.90
# DME claims 0.26 0.87 0.34 1.00 0.0633 8.48
# carrier claims 5.33 5.60 10.17 9.57 <0.001 61.71
# pharmacy visits among those with ≥1 pharmacy visit 7.62 7.02 5.50 6.91 <0.001 30.37
Medicaid: Number of Claims
# inpatient claims 0.08 0.40 0.23 0.56 <0.001 31.27
# long term care claims 3.01 4.28 2.50 4.53 0.0092 11.62
# Other therapy claims 3.82 7.88 6.10 9.57 <0.001 25.95
# pharmacy visits among those with ≥1 pharmacy visit 2.37 4.67 1.74 4.23 0.0009 14.17
2- months Follow-up All-cause Health Care Costs
Medicare:
Overall Costs
Inpatient stay costs $1435 $5664 $9678 $21206 <0.001 53.1
Outpatient costs $550 $1480 $527 $1292 0.6931 1.7
SNF costs $1452 $5049 $4939 $9091 <0.001 47.4
HSP costs $551 $2140 $610 $2202 0.5343 2.7
HHA costs $22 $474 $20 $391 0.918 0.4
DME costs $92 $412 $126 $457 0.0877 7.7
Carrier claims costs $835 $1882 $2463 $3677 <0.001 55.7
Pharmacy visit costs among those with ≥1 pharmacy visit $777 $914 $629 $963 0.0004 15.8
Total costs $5716 $10120 $18993 $27290 <0.001 64.5
Medicaid:
Overall Costs
Inpatient stay costs $316 $2807 $2715 $14083 <0.001 23.6
Long term care costs $6738 $5526 $5141 $5740 <0.001 28.4
Other therapy costs $696 $2337 $1590 $17513 0.1935 7.2
Pharmacy visit costs among those with ≥1 pharmacy visit $178 $650 $183 $809 0.8855 0.7
Total costs $7928 $7088 $9628 $24163 0.0757 9.5
Combined Medicare/Medicaid costs $13644 $11362 $28621 $33532 <0.001 59.8
CDI Clostridium difficile infection, DME Durable Medical Equipment, HHA Home Health Agency, HSP, Hospital Specific Portion, SD standard deviation, Std. Diff
standardized difference, SNF Skilled Nursing Facility
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of the groups most vulnerable to CDI, preventative mea-
sures are crucial to effectively prevent the disease. These
include additional nursing care, meticulous hand hygiene,
contact precautions, appropriate use of antimicrobials and
future interventions, such as vaccines. Accompanied by a
high increase in the incidence rate, high mortality associ-
ated with CDI was also observed. Although there is
limited data on long-term mortality, a few studies have
assessed 30-day mortality [4, 19] and our 30-day mortality
result (10.4%) is similar to these studies.
As the incidence of CDI continues to rise, health care
costs and utilization related to CDI will have a tremen-
dous impact on the health care system. Previous studies
reported costs attributable to CDI ranging from
$8,000–$30,000 that vary with coexisting conditions
[20]. However to our knowledge, no study has systemat-
ically assessed healthcare costs and utilization associated
with CDI in nursing homes where incidence of CDI is
quickly growing. Our study is unique since it used a
large data sample by linking Medicare, Medicaid, and
MDS; examined total health care costs including in-
patient, outpatient, SNF, and pharmacy costs; and pro-
vided an overall picture of the costs among residents in
a nursing home facility. Our study included both Medi-
care and Medicaid covered claims and expenses. Medi-
care covers relatively few LTC services, such as SNF and
home health care [21, 22]. Over 60% of nursing home
resident care, and an even higher percentage of long-
term resident care, is paid for by state Medicaid pro-
grams [23]. Thus, providing costs using both claims data
offers more generalizable results, helps to better under-
stand the true overall resource utilization, and indicates
that CDI is associated with high health care costs, espe-
cially among patients residing in nursing home facilities.
A few limitations should be noted for this study. We
included both Medicare and Medicaid claims data, but a
certain proportion of residents may have supplemental
long-term care insurance such as Medigap plans to fill
the ‘gaps’ that are not covered by Medicare plans. These
direct medical costs were not captured in this study. The
indirect costs, such as those associated with additional
nursing care, cleaning, isolation, and possible transmis-
sion to other patients, were also not accounted for in
this study. Therefore, this study underestimates the true
total burden of CDI among nursing home residents.
Given that Medicare and Medicaid data contain admin-
istrative information from multiple inpatient and out-
patient sources, under-reporting or misclassification of
health outcomes of interest may occur. Since we
required patients to have at least 2 MDS quarterly
assessments, the sample consisted entirely of long-term
stay residents. Patients who were in the nursing home
for a short amount of time and were discharged were
excluded from the study.
Although the Medicare, Medicaid, and MDS datasets
contain uniquely integrated data, its beneficiaries are
considered a vulnerable population since they are older
and have a higher disease burden. Our results demon-
strated an inverse distribution of CDI incidence as the
residents grew older. Few previous studies have also
demonstrated such an inverse trend among nursing
home residents; however, no explanations have been
provided [24, 25]. To verify our findings, we did a sensi-
tivity analysis to analyze the baseline CCI score and
medical costs across the age strata. We found a similar
inverse trend in which residents ≥85 years residing in
nursing homes had a lower comorbidity score, health
care utilization, and costs prior to the incident CDI
compared to patients aged 65–74 years and 75–84 years.
An explanation may be that older adults (≥85 years) are
more likely to reside in a nursing home facility due to
comorbid conditions and frailty, and younger seniors
(65–74) are more likely to reside in a nursing home fa-
cility due to poor health and may experience increased
health care exposures, putting them at a higher risk for
CDI.
Conclusions
Results from our study showed 3,753 cases per 100,000
person-years, 10.4% 30-day mortality, and $15,000 in
expenditures per case. With 1.4 million people residing
in nursing homes in the United States, [26, 27] we esti-
mated that approximately 53,000 annual CDI cases were
associated with 5,500 deaths and $800 million in costs
among this population. These numbers suggest that C.
difficile is endemic in nursing home facilities, and more
effective disease prevention and infection control
measures are warranted to prevent CDI and thus im-
prove patient outcomes and reduce overall health care
costs.
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